NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Thursday that its first quarter revenues rose 87 percent year over year, thanks to a corresponding 87 percent increase in testing volumes for its Cologuard noninvasive colon cancer screening test.

For the three months ended March 31, the molecular diagnostics company reported revenues of $90.3 million, up from $48.4 million in Q1 2017, and beating analysts' average estimate of $86.9 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.